The FDA has approved Prolastin-C (alpha1-proteinase inhibitor [human], from Talecris Biotherapeutics), a more concentrated formulation of Prolastin, for the treatment of alpha1-antitrypsin (AAT) ...
BARCELONA, Spain, July 13, 2023 (GLOBE NEWSWIRE) -- Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines, today announced it has met its ...
Talecris Biotherapeutics study shows that Prolastin-C (Alpha1-Proteinase Inhibitor [Human]) (A1PI) is as effective as Prolastin (Alpha1-Proteinase Inhibitor [Human]) in raising levels of alpha-1 ...
RESEARCH TRIANGLE PARK, N.C., Oct. 19 Talecris Biotherapeutics (Nasdaq: TLCR) today received approval from the U.S. Food and Drug Administration for PROLASTIN®-C (Alpha1-Proteinase Inhibitor [Human]), ...
PHILADELPHIA, May 22, 2013 /CNW/ - Grifols, a global healthcare company based in Barcelona, Spain, presented results from a study demonstrating that a higher dose of PROLASTIN ©-C (Alpha 1-Proteinase ...
Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifols’ Prolastin ®-C (Alpha1-Proteinase Inhibitor ...
Grifols’ advances in the science of alpha-1 underscore its robust innovation pipeline and commitment to testing and treatment for the alpha-1 community BARCELONA, Spain, July 13, 2023 (GLOBE NEWSWIRE) ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results